Search Results

363 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 09

    The ABOUT™ Toolbox: toward the development of consumer-reported outcome measures that matter

    CHREA C.(1); SPIES E.(1); AFOLALU E.(1); BACSO A.(1); CLERC E.(1); MAINY N.(1); BINGGELI P.(1); WEITKUNAT R.(1); ACQUADRO C.(2); SALZBERGER T.(3); CANO S.(4); ABETZ-WEBB L.(5); ROSE J.(6)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Mapi, an ICON plc Company, Lyon, France; (3) University of Economics and Business, Vienna, Austria; (4) ScaleReport, Ltd, Stotfold, U.K.; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (6) Rose Research Center, Raleigh, U.S.A.
    Tobacco harm reduction promotes the substitution of reduced-risk products (RRPs) for cigarettes by adult smokers who would otherwise continue to smoke, while preventing RRP initiation among non-users. To operationalize this public health strategy,...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 11

    Development and validation of the ABOUT™–Dependence measurement instrument to assess perceived dependence on tobacco and nicotine products

    AFOLALU E.(1); CHREA C.(1); SALZBERGER T.(2); ABETZ-WEBB L.(3); CANO S.(4); WEITKUNAT R.(1); ROSE J.(5)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) University of Economics and Business, Vienna, Austria; (3) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (4) Modus Outcomes, Letchworth Garden City, U.K.; (5) Rose Research Center, Raleigh, U.S.A.
    The development of the ABOUT™–Dependence measurement instrument was initiated to enable assessment of perceived dependence associated with the use of different tobacco and nicotine products (TNPs) and in users of multiple TNPs. We initially developed...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 57

    Cross-cultural equivalence of the ABOUT™–Perceived Risk instrument in seven languages

    CHREA C.(1); CANO S.(2); SALZBERGER T.(3); MAINY N.(1); ACQUADRO C.(4); POPIELNICKI A.(5); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Modus Outcomes, Letchworth Garden City, U.K.; (3) University of Economics and Business, Vienna, Austria; (4) Mapi Research Trust, ICON plc, Lyon, France; (5) TransPerfect, Linguistic Validation Group, Boston, MA, U.S.A.
    The risk of smoking has long been well understood by consumers. However, it is important to measure the perceived risks by consumers of novel smoke-free alternatives to cigarettes. The ABOUT™–Perceived Risk instrument was developed to allow the...
  4. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 019

    Simulated leachables assessment for critical components used in cartridges of electronic nicotine delivery systems

    CULBERT C.(1); WEIDMAN R.(2)
    (1) RAI Services Company, Winston-Salem, NC, USA; (2) R.J. Reynolds Tobacco Company, Winston-Salem, NC, USA
    Electronic Nicotine Delivery Systems (ENDS) contain e-liquid formulations that are heated to generate aerosols. The potential for chemicals to leach from the device materials into the e-liquid and transfer into the aerosol has been an area of...
  5. CORESTA Congress, Kunming, 2018, Agronomy/Phytopathology Groups, AP 01 (also presented at TSRC 2018)

    FDA advance notice of proposed rulemaking for nicotine level of combusted cigarettes – feasibility for compliance via tobacco plant genetics?

    HIATT E.
    R.J. Reynolds Tobacco Co., Winston-Salem, NC, U.S.A.
    On March 16, 2018, the U.S. Food and Drug Administration (FDA) published an advance notice of proposed rulemaking (ANPRM) entitled “Tobacco Product Standard for Nicotine Level of Combusted Cigarettes.” The publication of an ANPRM solicits information...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 58

    Developing fit-for-purpose self-report instruments for assessing consumer responses to tobacco and nicotine products: the ABOUT Toolbox initiative

    CHREA C.(1); SPIES E.(1); AFOLALU E.F.(1); MAINY N.(1); GALLOT S.(1); BINGGELI P.(1); CLERC E.(1); WEITKUNAT R.(1); SALZBERGER T.(2); CANO S.(3); ACQUADRO C.(4); ARNOULD B.(4); LAMBERT J.(4); BRUNEL V.(4); MARCUCCILLI C.(4); ABETZ-WEBB L.(5); ROSE J.(5); FAGERSTRÖM K.(5)
    (1) Philip Morris Products S.A.(part of Philip Morris International group of companies), Neuchâtel, Switzerland; (2) University of Economics and Business, Vienna, Austria; (3) ScaleReport, Ltd, Stotfold, U.K.; (4) Mapi, an ICON plc Company, Lyon, France; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield, Cheshire, U.K.; (6) Rose Research Center, Raleigh, NC, U.S.A.; (7) K. Fagerström Consulting AB, Vaxholm, Sweden
    Assessing the full potential of reduced risk products (RRP), for individual users and the population as a whole, requires the assessment of consumer perception and behavior associated with tobacco and nicotine products (TNP) with different exposure...